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Vaccines have a profound impact on global health, preventing illness, death, and improving the quality of 
life across the globe. However, the current costs of vaccine manufacturing and distribution often prevent 
the poorest segments of the world’s population from accessing these critical medicines.  
 
Vaccine manufacturing for global distribution typically requires large and expensive manufacturing facilities 
that result in high vaccine Cost of Goods and impede developing countries from initiating or expanding in-
country manufacturing capabilities.  
 
One of the strategies to address this is to intensify vaccine production processes. This presentation will give an 
overview of a project funded by the Bill & Melinda Gates foundation that focusses on applying the latest process 
intensification technologies to develop a platform that dramatically increases process efficiency, decreases 
production scale and reduces vaccine COGs to a price of $0.15 per dose or less. 
This vaccine manufacturing platform combines Vero cell lines optimized for virus propagation and media 
capable of supporting high cell density cell growth, high cell density single-use bioreactors and high efficiency 
and single step purification technologies. 
 
Together, these technologies enable vaccine yields to be significantly increased, which in turn allows 
commercial manufacturing in a small-footprint, low cost “micro-facility” capable of delivering >40M doses of 
vaccine per year for a CAPEX of not more than $10M and low operational costs. Such “micro-facilities” can be 
rapidly and inexpensively commissioned, drastically reducing vaccine COGs, facilitating rapid response and 
resulting in commercial manufacturing at lab scale. 
 
The platform is currently being established using Sabin IPV as the target vaccine. Current status is that Vero cell 
lines expressing 2-4 fold higher cell specific virus titers have been selected. These have been successfully 
cultured in high cell density, single-use bioreactors up to 40 million cells per mL. Following infection with Sabin 
poliovirus vaccine strains, a single chromatographic step using a novel membrane has resulted in 90% 
recoveries at 95% purity. 
 
For IPV, these yield intensifications mean that the entire commercial scale process can be operated in isolators 
in a footprint of ±30 m2. Combination of four of these manufacturing units in a single “micro-facility” would be 
capable of delivering >40 million doses of trivalent sIPV per year.  
 
Performance of the manufacturing process in isolators also allows the manufacture of viral vaccines that 
currently require high biological safety containment in an inexpensive facility design. This presentation will 
discuss the technologies used in the vaccine manufacturing platform and data obtained to date on Sabin IPV in 
more detail.  
